A potential supportive treatment as a preventive and adjuvant therapy in Covid-19 1
Immunomodulatory effect 2
- Up-regulates IFN-α production 2
- Increases antiviral activity 2
- Inhibits NF-κB signaling 2
- Limits cytokine storm in COVID-19 2
Reduces risk of bacterial co-infection 2
- Improves muco-ciliary clearance & barrier function of the respiratory epithelium 2
- Direct antibacterial effects against S. pneumoniae 2
Direct antiviral effect 2
- Inhibits SARS-CoV RNA polymerase, thus, blocking viral RNA replication
- Decreases activity of ACE2, a receptor for SARS-CoV-2 entry into human cells
Manages risk factors 2
Severe COVID-19 risk factors
Ageing, Diabetes, Atherosclerosis, Obesity, Immune deficiency
Zinc deficiency risk factors
(Zinc supplementation might be beneficial in managing these risk factors)
For the use of a Registered Medical Practitioner or a Hospital or a Laboratory use only.
COVID-19: Coronavirus disease of 2019. IFN: Interferon. NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells. SARS-CoV: Severe acute respiratory syndrome-related coronavirus. RNA: Ribonucleic acid. ACE2: Angiotensin converting enzyme 2
References: 1. Jayawardena R, Sooriyaarachchi P, Chourdakis M, et al. Enhancing immunity in viral infections, with special emphasis on COVID-19: A review. Diabetes Metab Syndr. 2020;14(4):367-382. 2. Skalny AV, Rink L, Ajsuvakova OP, et al. Zinc and respiratory tract infections: Perspectives for COVID-19 (Review). Int J Mol Med. 2020;46(1):17-26.